Crinetics Pharmaceuticals (CRNX) Current Leases (2021 - 2026)

Crinetics Pharmaceuticals has reported Current Leases for 6 years, with the latest figure at $6.5 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases fell 5.04% year-over-year to $6.5 million; the trailing twelve-month figure through Mar 2026 stood at $6.5 million (down 5.04% YoY), and the FY2025 full-year result was $6.5 million, down 9.27% from the prior year.
• Current Leases for Q1 2026 stood at $6.5 million, up from $6.5 million in the prior quarter.
• The five-year high for Current Leases was $7.4 million in Q2 2024, with the low at $1.0 million in Q3 2022.
• Average Current Leases over 5 years is $4.9 million, with a median of $6.4 million recorded in 2025.
• Year-over-year, Current Leases jumped 571.33% in 2024 and dropped 13.11% in 2025.
• Tracing CRNX's Current Leases over 5 years: stood at $1.1 million in 2022, then soared by 297.05% to $4.2 million in 2023, then surged by 71.39% to $7.2 million in 2024, then dropped by 9.27% to $6.5 million in 2025, then increased by 0.72% to $6.5 million in 2026.
• The last three Current Leases figures came in at $6.5 million (Q1 2026), $6.5 million (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.

Peer Comparison